CNSX:IMCC

IM Cannabis Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

IM Cannabis (CNSX:IMCC) Vs. RIV, WLLW, LABS, KHRN, DN, and META

Should you be buying IMCC stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to IM Cannabis, including RIV Capital (RIV), Willow Biosciences Inc. (WLLW.TO) (WLLW), MediPharm Labs (LABS), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), and Meta Growth (META).

RIV Capital (TSE:RIV) and IM Cannabis (CNSX:IMCC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Earnings & Valuation

This table compares RIV Capital and IM Cannabis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RIV CapitalC$15.44 million21.93$-106,223,568.00C($0.76)-3.19
IM CannabisN/AN/AN/AN/AN/A

IM Cannabis has lower revenue, but higher earnings than RIV Capital.

Analyst Recommendations

This is a summary of current ratings and target prices for RIV Capital and IM Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RIV Capital01002.00
IM Cannabis0000N/A

RIV Capital currently has a consensus target price of C$4.00, suggesting a potential upside of 65.29%.

Profitability

This table compares RIV Capital and IM Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RIV CapitalN/AN/AN/A
IM CannabisN/AN/AN/A

Summary

RIV Capital beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares IM Cannabis and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM CannabisN/AN/AN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)C$10,000.0017,504.06C$-51,032,952.00C($0.41)-3.43

IM Cannabis has higher earnings, but lower revenue than Willow Biosciences Inc. (WLLW.TO).

Analyst Ratings

This is a summary of current ratings for IM Cannabis and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IM Cannabis0000N/A
Willow Biosciences Inc. (WLLW.TO)0000N/A

Willow Biosciences Inc. (WLLW.TO) has a consensus price target of C$2.25, indicating a potential upside of 58.45%.

Profitability

This table compares IM Cannabis and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IM CannabisN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Summary

Willow Biosciences Inc. (WLLW.TO) beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and MediPharm Labs (TSE:LABS) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and MediPharm Labs' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM CannabisN/AN/AN/AN/AN/A
MediPharm LabsC$36.01 million3.72C$-123,815,040.00C($0.48)-1.08

IM Cannabis has higher earnings, but lower revenue than MediPharm Labs.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and MediPharm Labs, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IM Cannabis0000N/A
MediPharm Labs02023.00

MediPharm Labs has a consensus price target of C$1.53, indicating a potential upside of 194.23%.

Profitability

This table compares IM Cannabis and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IM CannabisN/AN/AN/A
MediPharm LabsN/AN/AN/A

Summary

MediPharm Labs beats IM Cannabis on 2 of the 2 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Khiron Life Sciences (CVE:KHRN) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Khiron Life Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM CannabisN/AN/AN/AN/AN/A
Khiron Life SciencesC$8.01 million10.69C$-39,493,921.00C($0.26)-2.17

IM Cannabis has higher earnings, but lower revenue than Khiron Life Sciences.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Khiron Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IM Cannabis0000N/A
Khiron Life Sciences0000N/A

Khiron Life Sciences has a consensus price target of C$1.20, indicating a potential upside of 110.53%.

Profitability

This table compares IM Cannabis and Khiron Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IM CannabisN/AN/AN/A
Khiron Life SciencesN/AN/AN/A

Summary

Khiron Life Sciences beats IM Cannabis on 1 of the 1 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Delta 9 Cannabis (TSE:DN) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Delta 9 Cannabis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM CannabisN/AN/AN/AN/AN/A
Delta 9 CannabisC$52.05 million1.16C$-7,346,808.00C($0.07)-8.19

IM Cannabis has higher earnings, but lower revenue than Delta 9 Cannabis.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Delta 9 Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IM Cannabis0000N/A
Delta 9 Cannabis00014.00

Delta 9 Cannabis has a consensus price target of C$1.24, indicating a potential upside of 110.17%.

Profitability

This table compares IM Cannabis and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IM CannabisN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Summary

Delta 9 Cannabis beats IM Cannabis on 2 of the 2 factors compared between the two stocks.

IM Cannabis (CNSX:IMCC) and Meta Growth (CVE:META) are both companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares IM Cannabis and Meta Growth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM CannabisN/AN/AN/AN/AN/A
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

IM Cannabis has higher earnings, but lower revenue than Meta Growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for IM Cannabis and Meta Growth, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IM Cannabis0000N/A
Meta Growth0000N/A

Profitability

This table compares IM Cannabis and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IM CannabisN/AN/AN/A
Meta GrowthN/AN/AN/A

Summary

Meta Growth beats IM Cannabis on 1 of the 1 factors compared between the two stocks.


IM Cannabis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RIV
RIV Capital
0.8$2.42flatC$338.68 millionC$15.44 million-3.19News Coverage
Gap Up
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.42flatC$175.04 millionC$10,000.00-3.43Gap Up
LABS
MediPharm Labs
1.3$0.52flatC$134.13 millionC$36.01 million-1.08Gap Up
KHRN
Khiron Life Sciences
0.9$0.57flatC$67.34 millionC$8.01 million-2.17
DN
Delta 9 Cannabis
1.4$0.59flatC$60.20 millionC$52.05 million-8.19News Coverage
Gap Down
META
Meta Growth
0.8$0.14flatC$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.20flatC$36.44 millionC$17.36 million-0.76Gap Down
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.